Abstract 1394P
Background
BRAF and cMET Exon 14 skipping are rare mutations of NSCLC. Opposite to other alterations, the preferred treatment sequencing in 1st and 2nd line is not clear.
Methods
We created an international registry for patients (pts) with advanced NSCLC harboring BRAF and cMET exon 14 skipping mutations, diagnosed from Jan 2017 until June 2022, excluding pts enrolled in clinical trials. Clinicopathologic and molecular data were collected, and treatment patterns were recorded. Clinical endpoints according to treatment assignment were assessed using Kaplan-Meier curves and Cox regression models.
Results
Data on 58 pts from 7 centers across 5 countries were included in the final analysis. Forty patients had cMET exon 14 skipping mutation and 18 had BRAF V600E mutation. Main characteristics: median age 66.7 (range: 36.0-91.0) years, female sex (48.0%), never or past smokers (71.0%), performance status 0-1 in (84.0%), adenocarcinoma (86.2%), stage IIIC - IV at diagnosis (82.2%), bone and brain metastasis (45.0%, and 21.0%, respectively). Mutations were uniformly diagnosed by NGS in all centers. Programmed death-ligand 1 TPS was <1% in 18%, 1-49% in 34% and >50% in 48% of cases. Fifty-three and 28 pts received 1st and 2nd line treatments, respectively, among which 52.8% received targeted therapy (TT) in 1st line and 53.5% in 2nd line. Overall response rate (ORR) and disease control rate (DCR) for 1st line treatment with TT vs. other (IO +/- CT ) was 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs 39.1% (p = 0.04), respectively. Type of treatment in 1st line (TT vs. IO +/- CT) affected Time to Treatment Discontinuation (TTD), 11.6 m vs. 4.6 m, p = 0.006. Overall survival for the whole group was 15.4 m and was not statistically influenced by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).
Conclusions
This real-world retrospective study suggests that TT in the 1st line is the preferred option for the treatment of pts with advanced NSCLC with BRAF and cMET exon 14 skipping mutations, as opposed to IO +/- CT, due to higher ORR and DCR, longer TTD and the fact that almost half of the patients did not receive 2nd line treatment. U Janzic and W. Shalata contributed equally to this study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
U. Janzic: Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca, Roche, Pfizer; Financial Interests, Personal and Institutional, Advisory Board: MSD, BMS, Takeda, Amgen, Boehringer Ingelheim; Financial Interests, Institutional, Other: Novartis. W. Shalata, A. Agbarya, R. Dziadziuszko, M. Jakopovic: Financial Interests, Personal and Institutional, Advisory Board: Roche, AstraZeneca, MSD, Pfizer, Novartis, BMS. K. Szymczak: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, Novartis, BMS, Amgen, Vipharm. G. Mountzios: Financial Interests, Personal and Institutional, Advisory Board: Roche, AstraZeneca, MSD, BMS, Gilead, Pfizer, Boehringer Ingelheim, Novartis, Amgen, Mirati, Bioatlas. A. Pluzanski: Financial Interests, Personal and Institutional, Advisory Board: BMS, MSD, AstraZeneca, Roche.
Resources from the same session
1464P - Impact of age on the benefit of immunotherapy for metastatic squamous cell lung cancer: An NCDB database analysis
Presenter: Zhonglin Hao
Session: Poster session 20
1465P - Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study
Presenter: Hayato Kawachi
Session: Poster session 20
1467P - Combination therapy of envafolimab and suvemcitug with chemotherapy in patients with non-small cell lung cancer (NSCLC): Results from a phase II clinical trial
Presenter: Chunjiao Wu
Session: Poster session 20